The role of interleukin-6 in gynaecological malignancies

Cytokine and Growth Factor Reviews

Volumn 23, Issue 6, 2012, Pages 333-342

  Coward, Jermaine I G ^a   Kulbe, Hagen ^b  

^a MATER MEDICAL RESEARCH INSTITUTE   (Australia)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cervical cancer; Endometrial cancer; Epithelial ovarian cancer; Interleukin 6; Tumour microenvironment

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANTISENSE OLIGONUCLEOTIDE; CA 125 ANTIGEN; CARBOPLATIN; CILIARY NEUROTROPHIC FACTOR; CISPLATIN; DOXORUBICIN; GLYCOPROTEIN GP 130; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 11; INTERLEUKIN 27; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; JANUS KINASE 1; JANUS KINASE 2; LEUKEMIA INHIBITORY FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; ONCOSTATIN M; PACLITAXEL; PEGINTERFERON ALPHA2B; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; SILTUXIMAB; SMALL INTERFERING RNA; STAT PROTEIN; TOCILIZUMAB; TRANSCRIPTION FACTOR NRF2; UNINDEXED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTOCRINE EFFECT; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; DRUG RESISTANCE; DRUG TARGETING; ENDOMETRIUM CANCER; GYNECOLOGIC CANCER; HUMAN; NONHUMAN; OVARY CANCER; PERITONEAL FLUID LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR VASCULARIZATION; UTERINE CERVIX CANCER;

ANIMALS; ASCITIC FLUID; DRUG RESISTANCE, NEOPLASM; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; INTERLEUKIN-6; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 84869886769     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2012.08.005     Document Type: Short Survey

References (125)

1. Modugno F., Ness R.B., Chen C., Weiss N.S. Inflammation and endometrial cancer: a hypothesis. Cancer Epidemiology, Biomarkers and Prevention 2005, 14:2840-2847.
2. He Y.Y., Cai B., Yang Y.X., Liu X.L., Wan X.P. Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway. Cancer Science 2009, 100:1051-1061.
3. Seo K.H., Lee H.S., Jung B., Ko H.M., Choi J.H., Park S.J., et al. Estrogen enhances angiogenesis through a pathway involving platelet-activating factor-mediated nuclear factor-kappaB activation. Cancer Research 2004, 64(18):6482-6488.
4. Makinoda S., Hirosaki N., Waseda T., Tomizawa H., Fujii R. Granulocyte colony-stimulating factor (G-CSF) in the mechanism of human ovulation and its clinical usefulness. Current Medicinal Chemistry 2008, 15:604-613.
5. Espey L.L. Current status of the hypothesis that mammalian ovulation is comparable to an inflammatory reaction. Biology of Reproduction 1994, 50:233-238.
6. Castle P.E., Hillier S.L., Rabe L.K., Hildesheim A., Herrero R., Bratti M.C., et al. An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). Cancer Epidemiology, Biomarkers and Prevention 2001, 10(10):1021-1027.
7. Yang Y.C., Chang C.L., Huang Y.W., Wang D.Y. Possible cofactor in cervical carcinogenesis: proliferation index of the transformation zone in cervicitis. Chang Gung Medical Journal 2001, 24:615-620.
8. Schwebke J.R., Zajackowski M.E. Effect of concurrent lower genital tract infections on cervical cancer screening. Genitourinary Medicine 1997, 73:383-386.
9. Kemp T.J., Hildesheim A., Garcia-Pineres A., Williams M.C., Shearer G.M., Rodriguez A.C., et al. Elevated systemic levels of inflammatory cytokines in older women with persistent cervical human papillomavirus infection. Cancer Epidemiology, Biomarkers and Prevention 2010, 19(8):1954-1959.
10. Goswami B., Rajappa M., Sharma M., Sharma A. Inflammation: its role and interplay in the development of cancer, with special focus on gynecological malignancies. International Journal of Gynecological Cancer 2008, 18:591-599.
11. Jabbour H.N., Sales K.J., Catalano R.D., Norman J.E. Inflammatory pathways in female reproductive health and disease. Reproduction 2009, 138:903-919.
12. Aghajanian C., Sill M.W., Darcy K.M., Greer B., McMeekin D.S., Rose P.G., et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Journal of Clinical Oncology 2011, 29(16):2259-2265.
13. Burger R.A. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. Journal of Clinical Oncology 2010, 28.
14. Coward J., Kulbe H., Chakravarty P., Leader D., Vassileva V., Leinster D.A., et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clinical Cancer Research 2011, 17(18):6083-6096.
15. Kristensen G. ICON7 phase III randomized trial of bevcacizumab in women with newly diagnosed ovarian cancer. Journal of Clinical Oncology 2011, 29(Suppl.). Abstract No: LBA5006.
16. Monk B.J., Sill M.W., Burger R.A., Gray H.J., Buekers T.E., Roman L.D. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. Journal of Clinical Oncology 2009, 27:1069-1074.
17. Madhusudan S., Muthuramalingam S.R., Braybrooke J.P., Wilner S., Kaur K., Han C., et al. Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. Journal of Clinical Oncology 2005, 23(25):5950-5959.
18. Burger R.A., Brady M.F., Bookman M.A., Fleming G.F., Monk B.J., Huang H., et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. New England Journal of Medicine 2011, 365(26):2473-2483.
19. Perren T.J., Swart A.M., Pfisterer J., Ledermann J.A., Pujade-Lauraine E., Kristensen G., et al. A phase 3 trial of bevacizumab in ovarian cancer. New England Journal of Medicine 2011, 365(26):2484-2496.
20. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
21. Kulbe H., Chakravarty P., Leinster D.A., Charles K.A., Kwong J., Thompson R.G., et al. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Research 2012, 72:66-75.
22. Jones S.A., Scheller J., Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. Journal of Clinical Investigation 2011, 121:3375-3383.
23. Horiuchi S., Koyanagi Y., Zhou Y., Miyamoto H., Tanaka Y., Waki M., et al. Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. European Journal of Immunology 1994, 24(8):1945-1948.
24. Mullberg J., Schooltink H., Stoyan T., Gunther M., Graeve L., Buse G., et al. The soluble interleukin-6 receptor is generated by shedding. European Journal of Immunology 1993, 23(2):473-480.
25. Montero-Julian F.A., Brailly H., Sautes C., Joyeux I., Dorval T., Mosseri V., et al. Characterization of soluble gp130 released by melanoma cell lines: A polyvalent antagonist of cytokines from the interleukin 6 family. Clinical Cancer Research 1997, 3(8):1443-1451.
26. Jones S.A., Horiuchi S., Topley N., Yamamoto N., Fuller G.M. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB Journal 2001, 15:43-58.
27. Scheller J., Ohnesorge N., Rose-John S. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scandinavian Journal of Immunology 2006, 63:321-329.
28. Murakami-Mori K., Taga T., Kishimoto T., Nakamura S. The soluble form of the IL-6 receptor (sIL-6R alpha) is a potent growth factor for AIDS-associated Kaposi's sarcoma (KS) cells; the soluble form of gp130 is antagonistic for sIL-6R alpha-induced AIDS-KS cell growth. International Immunology 1996, 8:595-602.
29. Muller-Newen G., Kuster A., Hemmann U., Keul R., Horsten U., Martens A., et al. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. Journal of Immunology 1998, 161(11):6347-6355.
30. Garbers C., Thaiss W., Jones G.W., Waetzig G.H., Lorenzen I., Guilhot F., et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. Journal of Biological Chemistry 2011, 286(50):42959-42970.
31. Muller-Newen G. The cytokine receptor gp130: faithfully promiscuous. Sci STKE 2003 2003, PE40.
32. Autissier P., De Vos J., Liautard J., Tupitsyn N., Jacquet C., Chavdia N., et al. Dimerization and activation of the common transducing chain (gp130) of the cytokines of the IL-6 family by mAb. International Immunology 1998, 10(12):1881-1889.
33. Hirano T., Nakajima K., Hibi M. Signaling mechanisms through gp130: a model of the cytokine system. Cytokine and Growth Factor Reviews 1997, 8:241-252.
34. Hodge D.R., Hurt E.M., Farrar W.L. The role of IL-6 and STAT3 in inflammation and cancer. European Journal of Cancer 2005, 41:2502-2512.
35. Catalano S., Giordano C., Rizza P., Gu G., Barone I., Bonofiglio D., et al. Evidence that leptin through STAT and CREB signaling enhances cyclin D1 expression and promotes human endometrial cancer proliferation. Journal of Cellular Physiology 2009, 218(3):490-500.
36. Huang M., Page C., Reynolds R.K., Lin J. Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. Gynecologic Oncology 2000, 79:67-73.
37. Silver D.L., Naora H., Liu J., Cheng W., Montell D.J. Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Research 2004, 64:3550-3558.
38. Takemoto S., Ushijima K., Kawano K., Yamaguchi T., Terada A., Fujiyoshi N., et al. Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma. British Journal of Cancer 2009, 101(6):967-972.
39. Chen C.L., Hsieh F.C., Lieblein J.C., Brown J., Chan C., Wallace J.A., et al. Stat3 activation in human endometrial and cervical cancers. British Journal of Cancer 2007, 96(4):591-599.
40. Yang J., Chatterjee-Kishore M., Staugaitis S.M., Nguyen H., Schlessinger K., Levy D.E., et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Research 2005, 65(3):939-947.
41. Sasse J., Hemmann U., Schwartz C., Schniertshauer U., Heesel B., Landgraf C., et al. Mutational analysis of acute-phase response factor/Stat3 activation and dimerization. Molecular and Cellular Biology 1997, 17(8):4677-4686.
42. Nicholson S.E., De Souza D., Fabri L.J., Corbin J., Willson T.A., Zhang J.G., et al. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proceedings of the National Academy of Sciences of the United States of America 2000, 97(12):6493-6498.
43. Li Y., Deuring J., Peppelenbosch M.P., Kuipers E.J., de Haar C., van der Woude C.J. IL-6-induced DNMT1 activity mediates SOCS3 promoter hypermethylation in ulcerative colitis-related colorectal cancer. Carcinogenesis 2012.
44. Niu G., Wright K.L., Huang M., Song L., Haura E., Turkson J., et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21(13):2000-2008.
45. Wang T., Niu G., Kortylewski M., Burdelya L., Shain K., Zhang S., et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nature Medicine 2004, 10(1):48-54.
46. Watson J.M., Sensintaffar J.L., Berek J.S., Martinez-Maza O. Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Research 1990, 50:6959-6965.
47. Anglesio M.S., George J., Kulbe H., Friedlander M., Rischin D., Lemech C., et al. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clinical Cancer Research 2011, 17(8):2538-2548.
48. Watson J.M., Berek J.S., Martinez-Maza O. Growth inhibition of ovarian cancer cells induced by antisense IL-6 oligonucleotides. Gynecologic Oncology 1993, 49:8-15.
49. Das C., Kumar V.S., Gupta S., Kumar S. Network of cytokines, integrins and hormones in human trophoblast cells. Journal of Reproductive Immunology 2002, 53:257-268.
50. Wang P., Li N., Li J.S., Li W.Q. The role of endotoxin, TNF-alpha, and IL-6 in inducing the state of growth hormone insensitivity. World Journal of Gastroenterology 2002, 8:531-536.
51. Slater M., Cooper M., Murphy C.R. Human growth hormone and interleukin-6 are upregulated in endometriosis and endometrioid adenocarcinoma. Acta Histochemica 2006, 108:13-18.
52. Bellone S., Watts K., Cane S., Palmieri M., Cannon M.J., Burnett A., et al. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecologic Oncology 2005, 98(1):92-98.
53. Castrilli G., Tatone D., Diodoro M.G., Rosini S., Piantelli M., Musiani P. Interleukin 1alpha and interleukin 6 promote the in vitro growth of both normal and neoplastic human cervical epithelial cells. British Journal of Cancer 1997, 75:855-859.
54. Eustace D., Han X., Gooding R., Rowbottom A., Riches P., Heyderman E. Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro. Gynecologic Oncology 1993, 50:15-19.
55. Takano H., Harigaya K., Ishii G., Sugaya Y., Soeta S., Nunoyama T., et al. Interleukin-6 (IL-6) production in carcinoma of the cervix. Archives of Gynecology and Obstetrics 1996, 258(1):25-33.
56. Wei L.H., Kuo M.L., Chen C.A., Chou C.H., Cheng W.F., Chang M.C., et al. The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway. Oncogene 2001, 20(41):5799-5809.
57. Guo Y., Nemeth J., O'Brien C., Susa M., Liu X., Zhang Z., et al. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. Clinical Cancer Research 2010, 16(23):5759-5769.
58. Song M., Kellum J.A. Interleukin-6. Critical Care Medicine 2005, 33:S463-S465.
59. Heikkila K., Ebrahim S., Lawlor D.A. Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. European Journal of Cancer 2008, 44:937-945.
60. Stone R.L., Nick A.M., McNeish I.A., Balkwill F., Han H.D., Bottsford-Miller J., et al. Paraneoplastic thrombocytosis in ovarian cancer. New England Journal of Medicine 2012, 366(7):610-618.
61. Berek J.S., Chung C., Kaldi K., Watson J.M., Knox R.M., Martinez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. American Journal of Obstetrics and Gynecology 1991, 164:1038-1042. discussion 1038-1042.
62. Tempfer C., Zeisler H., Sliutz G., Haeusler G., Hanzal E., Kainz C. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecologic Oncology 1997, 66:27-30.
63. Scambia G., Testa U., Benedetti Panici P., Foti E., Martucci R., Gadducci A., et al. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. British Journal of Cancer 1995, 71(2):354-356.
64. Chopra V., Dinh T.V., Hannigan E.V. Serum levels of interleukins, growth factors and angiogenin in patients with endometrial cancer. Journal of Cancer Research and Clinical Oncology 1997, 123:167-172.
65. Chopra V., Dinh T.V., Hannigan E.V. Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer. Cancer Investigation 1998, 16:152-159.
66. Punnonen R., Teisala K., Kuoppala T., Bennett B., Punnonen J. Cytokine production profiles in the peritoneal fluids of patients with malignant or benign gynecologic tumors. Cancer 1998, 83:788-796.
67. Offner F.A., Obrist P., Stadlmann S., Feichtinger H., Klingler P., Herold M., et al. IL-6 secretion by human peritoneal mesothelial and ovarian cancer cells. Cytokine 1995, 7(6):542-547.
68. May L.T., Viguet H., Kenney J.S., Ida N., Allison A.C., Sehgal P.B. High levels of " complexed" interleukin-6 in human blood. Journal of Biological Chemistry 1992, 267:19698-19704.
69. Plante M., Rubin S.C., Wong G.Y., Federici M.G., Finstad C.L., Gastl G.A. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 1994, 73:1882-1888.
70. Lane D., Matte I., Rancourt C., Piche A. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer 2011, 11:210.
71. Kutteh W.H., Kutteh C.C. Quantitation of tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 in the effusions of ovarian epithelial neoplasms. American Journal of Obstetrics and Gynecology 1992, 167:1864-1869.
72. Kryczek I., Grybos M., Karabon L., Klimczak A., Lange A. IL-6 production in ovarian carcinoma is associated with histiotype and biological characteristics of the tumour and influences local immunity. British Journal of Cancer 2000, 82:621-628.
73. Lo C.W., Chen M.W., Hsiao M., Wang S., Chen C.A., Hsiao S.M., et al. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Research 2011, 71(2):424-434.
74. Clahsen T., Schaper F. Interleukin-6 acts in the fashion of a classical chemokine on monocytic cells by inducing integrin activation, cell adhesion, actin polymerization, chemotaxis, and transmigration. Journal of Leukocyte Biology 2008, 84:1521-1529.
75. Lin M.T., Lin B.R., Chang C.C., Chu C.Y., Su H.J., Chen S.T., et al. IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src/RhoA/ROCK signaling pathway. International Journal of Cancer 2007, 120(12):2600-2608.
76. Liu Q., Li G., Li R., Shen J., He Q., Deng L., et al. IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines. Journal of Neuro-Oncology 2010, 100(2):165-176.
77. Lederle W., Depner S., Schnur S., Obermueller E., Catone N., Just A., et al. IL-6 promotes malignant growth of skin SCCs by regulating a network of autocrine and paracrine cytokines. International Journal of Cancer 2011, 128(12):2803-2814.
78. Colomiere M., Ward A.C., Riley C., Trenerry M.K., Cameron-Smith D., Findlay J., et al. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. British Journal of Cancer 2009, 100(1):134-144.
79. Obata N.H., Tamakoshi K., Shibata K., Kikkawa F., Tomoda Y. Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Research 1997, 17:337-342.
80. Wang Y., Li L., Guo X., Jin X., Sun W., Zhang X., et al. Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine 2012.
81. Rabinovich A., Medina L., Piura B., Segal S., Huleihel M. Regulation of ovarian carcinoma SKOV-3 cell proliferation and secretion of MMPs by autocrine IL-6. Anticancer Research 2007, 27:267-272.
82. Tsukamoto H., Shibata K., Kajiyama H., Terauchi M., Nawa A., Kikkawa F. Uterine smooth muscle cells increase invasive ability of endometrial carcinoma cells through tumor-stromal interaction. Clinical and Experimental Metastasis 2007, 24:423-429.
83. Choi D.S., Kim H.J., Yoon J.H., Yoo S.C., Jo H., Lee S.Y., et al. Endometrial cancer invasion depends on cancer-derived tumor necrosis factor-alpha and stromal derived hepatocyte growth factor. International Journal of Cancer 2009, 124(11):2528-2538.
84. Sales K.J., Boddy S.C., Jabbour H.N. F-prostanoid receptor alters adhesion, morphology and migration of endometrial adenocarcinoma cells. Oncogene 2008, 27:2466-2477.
85. Wei L.H., Kuo M.L., Chen C.A., Cheng W.F., Cheng S.P., Hsieh F.J., et al. Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor. Gynecologic Oncology 2001, 82(1):49-56.
86. Karst A.M., Gao K., Nelson C.C., Li G. Nuclear factor kappa B subunit p50 promotes melanoma angiogenesis by upregulating interleukin-6 expression. International Journal of Cancer 2009, 124:494-501.
87. Huang S.P., Wu M.S., Shun C.T., Wang H.P., Lin M.T., Kuo M.L., et al. Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. Journal of Biomedical Science 2004, 11(4):517-527.
88. Wei L.H., Kuo M.L., Chen C.A., Chou C.H., Lai K.B., Lee C.N., et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 2003, 22(10):1517-1527.
89. Su J.L., Lai K.P., Chen C.A., Yang C.Y., Chen P.S., Chang C.C., et al. A novel peptide specifically binding to interleukin-6 receptor (gp80) inhibits angiogenesis and tumor growth. Cancer Research 2005, 65(11):4827-4835.
90. Motro B., Itin A., Sachs L., Keshet E. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proceedings of the National Academy of Sciences of the United States of America 1990, 87:3092-3096.
91. Nilsson M.B., Langley R.R., Fidler I.J. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Research 2005, 65:10794-10800.
92. Lang S.A., Moser C., Gaumann A., Klein D., Glockzin G., Popp F.C., et al. Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth. Clinical Cancer Research 2007, 13(21):6459-6468.
93. Duluc D., Delneste Y., Tan F., Moles M.P., Grimaud L., Lenoir J., et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 2007, 110(13):4319-4330.
94. Allavena P., Sica A., Solinas G., Porta C., Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Critical Reviews in Oncology/Hematology 2008, 66:1-9.
95. Korn T., Mitsdoerffer M., Croxford A.L., Awasthi A., Dardalhon V.A., Galileos G., et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(47):18460-18465.
96. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441(7090):235-238.
97. Miyahara Y., Odunsi K., Chen W., Peng G., Matsuzaki J., Wang R.F. Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:15505-15510.
98. Kato T., Furumoto H., Ogura T., Onishi Y., Irahara M., Yamano S., et al. Expression of IL-17 mRNA in ovarian cancer. Biochemical and Biophysical Research Communications 2001, 282(3):735-738.
99. Fujimoto J. Novel therapeutic strategy for uterine endometrial cancers. International Journal of Clinical Oncology 2008, 13:411-415.
100. Hashimoto I., Kodama J., Seki N., Hongo A., Miyagi Y., Yoshinouchi M., et al. Macrophage infiltration and angiogenesis in endometrial cancer. Anticancer Research 2000, 20(6C):4853-4856.
101. Guo Y., Xu F., Lu T., Duan Z., Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treatment Reviews 2012, 38(7):904-910.
102. Wang Y., Niu X.L., Qu Y., Wu J., Zhu Y.Q., Sun W.J., et al. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Letters 2010, 295(1):110-123.
103. Duan Z., Foster R., Bell D.A., Mahoney J., Wolak K., Vaidya A., et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clinical Cancer Research 2006, 12(17):5055-5063.
104. Wruck C.J., Streetz K., Pavic G., Gotz M.E., Tohidnezhad M., Brandenburg L.O., et al. Nrf2 induces interleukin-6 (IL-6) expression via an antioxidant response element within the IL-6 promoter. Journal of Biological Chemistry 2011, 286(6):4493-4499.
105. Jiang T., Chen N., Zhao F., Wang X.J., Kong B., Zheng W., et al. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Research 2010, 70(13):5486-5496.
106. Ma X., Zhang J., Liu S., Huang Y., Chen B., Wang D. Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer. Cancer Chemotherapy and Pharmacology 2012, 69:485-494.
107. Gagnon V., Mathieu I., Sexton E., Leblanc K., Asselin E. AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecologic Oncology 2004, 94:785-795.
108. Balkwill F.R., Coward J., Kulbe H., Milagre C., Gopinathan G., McNeish I.A. IL-6 and ovarian cancer - response. Clinical Cancer Research 2011, 17:7838.
109. Aghajanian C., Blank S.V., Goff B.A., Judson P.L., Teneriello M.G., Husain A., et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. Journal of Clinical Oncology 2012, 30(17):2039-2045.
110. Poth K.J., Guminski A.D., Thomas G.P., Leo P.J., Jabbar I.A., Saunders N.A. Cisplatin treatment induces a transient increase in tumorigenic potential associated with high interleukin-6 expression in head and neck squamous cell carcinoma. Molecular Cancer Therapeutics 2010, 9:2430-2439.
111. Wang T.H., Chan Y.H., Chen C.W., Kung W.H., Lee Y.S., Wang S.T., et al. Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways. Oncogene 2006, 25(35):4857-4866.
112. Santin A.D., Zhan F., Cane S., Bellone S., Palmieri M., Thomas M., et al. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. British Journal of Cancer 2005, 92(8):1561-1573.
113. Tartour E., Gey A., Sastre-Garau X., Pannetier C., Mosseri V., Kourilsky P., et al. Analysis of interleukin 6 gene expression in cervical neoplasia using a quantitative polymerase chain reaction assay: evidence for enhanced interleukin 6 gene expression in invasive carcinoma. Cancer Research 1994, 54(23):6243-6248.
114. Enomoto T., Inoue M., Perantoni A.O., Terakawa N., Tanizawa O., Rice J.M. K-ras activation in neoplasms of the human female reproductive tract. Cancer Research 1990, 50:6139-6145.
115. Tashiro H., Blazes M.S., Wu R., Cho K.R., Bose S., Wang S.I., et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Research 1997, 57(18):3935-3940.
116. Daikoku T., Hirota Y., Tranguch S., Joshi A.R., DeMayo F.J., Lydon J.P., et al. Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. Cancer Research 2008, 68(14):5619-5627.
117. St-Germain M.E., Gagnon V., Parent S., Asselin E. Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NF-kappaB/IkappaB pathway. Molecular Cancer 2004, 3:7.
118. Cheung T.H., Lo K.W., Yim S.F., Chan L.K., Heung M.S., Chan C.S., et al. Epigenetic and genetic alternation of PTEN in cervical neoplasm. Gynecologic Oncology 2004, 93(3):621-627.
119. Rizvi M.M., Alam M.S., Ali A., Mehdi S.J., Batra S., Mandal A.K. Aberrant promoter methylation and inactivation of PTEN gene in cervical carcinoma from Indian population. Journal of Cancer Research and Clinical Oncology 2011, 137:1255-1262.
120. Pappa K.I., Choleza M., Markaki S., Giannikaki E., Kyroudi A., Vlachos G., et al. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status. Gynecologic Oncology 2006, 100(3):596-600.
121. Shih Ie M., Kurman R.J. Ovarian tumorigenesis: a proposed model based on morphological molecular genetic analysis. American Journal of Pathology 2004, 164:1511-1518.
122. Fujimoto J., Sakaguchi H., Aoki I., Tamaya T. Clinical implications of expression of interleukin 8 related to angiogenesis in uterine cervical cancers. Cancer Research 2000, 60:2632-2635.
123. Wan T., Liu J.H., Zheng L.M., Cai M.Y., Ding T. Prognostic significance of tumor-associated macrophage infiltration in advanced epithelial ovarian carcinoma. Ai Zheng 2009, 28:323-327.
124. Zhang J.P., Lu W.G., Ye F., Chen H.Z., Zhou C.Y., Xie X. Study on CXCR4/SDF-1alpha axis in lymph node metastasis of cervical squamous cell carcinoma. International Journal of Gynecological Cancer 2007, 17:478-483.
125. Milliken D., Scotton C., Raju S., Balkwill F., Wilson J. Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clinical Cancer Research 2002, 8:1108-1114.